Andreas Sutter
YOU?
Author Swipe
View article: Discovery of IRAK4 Inhibitors <b>BAY1834845</b> (Zabedosertib) and <b>BAY1830839</b>
Discovery of IRAK4 Inhibitors <b>BAY1834845</b> (Zabedosertib) and <b>BAY1830839</b> Open
Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in innate inflammatory processes. Here, we describe the discovery of two clinical candidate IRAK4 inhibitors, BAY1834845 (zabedosertib) and BAY1830839, …
View article: De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma Open
View article: DNA repair inhibitors sensitize cells differently to high and low LET radiation
DNA repair inhibitors sensitize cells differently to high and low LET radiation Open
View article: De Novo Pyrimidine Synthesis is a Targetable Vulnerability in IDH Mutant Glioma
De Novo Pyrimidine Synthesis is a Targetable Vulnerability in IDH Mutant Glioma Open
SUMMARY Mutations affecting isocitrate dehydrogenase (IDH) enzymes are prevalent in glioma, leukemia, and other cancers. Although mutant IDH inhibitors are effective against leukemia, they appear less active in aggressive glioma, underscor…
View article: Identification of De Novo Pyrimidine Synthesis as a Targetable Vulnerability in a Novel IDH1 Mutant Engineered Astrocytoma Model
Identification of De Novo Pyrimidine Synthesis as a Targetable Vulnerability in a Novel IDH1 Mutant Engineered Astrocytoma Model Open
View article: DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA
DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA Open
70–90% of lower-grade gliomas and secondary glioblastomas harbor gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1), causing overproduction of the oncometabolite (R)-2-hydroxyglutarate [(R)-2HG]. Although inhibitors of mutant …
View article: Schwemmholz und Rutschungen
Schwemmholz und Rutschungen Open
View article: Diskussion der Unsicherheiten und Limitationen
Diskussion der Unsicherheiten und Limitationen Open
View article: Image analysis of mechanistic protein biomarkers for the characterization of genotoxicants: Aneugens, clastogens, and reactive oxygen species inducers
Image analysis of mechanistic protein biomarkers for the characterization of genotoxicants: Aneugens, clastogens, and reactive oxygen species inducers Open
The early detection of genotoxicity contributes to cutting‐edge drug discovery and development, requiring effective identification of genotoxic hazards posed by drugs while providing mode of action (MoA) information in a high throughput ma…
View article: Radiobiological effects of the alpha emitter Ra-223 on tumor cells
Radiobiological effects of the alpha emitter Ra-223 on tumor cells Open
Targeted alpha therapy is an emerging innovative approach for the treatment of advanced cancers, in which targeting agents deliver radionuclides directly to tumors and metastases. The biological effects of α-radiation are still not fully u…
View article: Classification of in vitro genotoxicants using a novel multiplexed biomarker assay compared to the flow cytometric micronucleus test
Classification of in vitro genotoxicants using a novel multiplexed biomarker assay compared to the flow cytometric micronucleus test Open
Regulatory in vitro genotoxicity testing exhibits shortcomings in specificity and mode of action (MoA) information. Thus, the aim of this work was to evaluate the performance of the novel MultiFlow ® assay composed of mechanistic biomarker…
View article: Interlaboratory evaluation of a multiplexed high information content in vitro genotoxicity assay
Interlaboratory evaluation of a multiplexed high information content in vitro genotoxicity assay Open
We previously described a multiplexed in vitro genotoxicity assay based on flow cytometric analysis of detergent‐liberated nuclei that are simultaneously stained with propidium iodide and labeled with fluorescent antibodies against p53, γH…
View article: Genotoxicity assessment of peptide/protein-related biotherapeutics: points to consider before testing
Genotoxicity assessment of peptide/protein-related biotherapeutics: points to consider before testing Open
The ICH S6(R1) recommendations on safety evaluation of biotherapeutics have led to uncertainty in determining what would constitute a cause for concern that would require genotoxicity testing. A Health and Environmental Sciences Institute'…